RefluxStop
Beyond's analysis on RefluxStop
- — Implantica announces a Capital Markets Day in Stockholm to showcase its medtech pipeline, including RefluxStop®, aiming to attract investor interest in its $1 billion acid‑reflux market
- — FDA approves Implantica's RefluxStop, clearing the way for US market entry of a new GERD treatment device
- — FDA approval clears the way for Implantica’s RefluxStop to enter the U.S. GERD treatment market
Recent news mentioning RefluxStop
- — Implantica's RefluxStop® U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception
- — Implantica's RefluxStop® U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception
- — Implantica receives FDA approval for RefluxStop® - Opening the U.S. market
- — Implantica receives FDA approval for RefluxStop® - Opening the U.S. market